258 related articles for article (PubMed ID: 26927578)
1. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment.
Saloner B; Stoller KB; Barry CL
Psychiatr Serv; 2016 Jun; 67(6):676-9. PubMed ID: 26927578
[TBL] [Abstract][Full Text] [Related]
2. Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.
Bachhuber MA; Mehta PK; Faherty LJ; Saloner B
Med Care; 2017 Dec; 55(12):985-990. PubMed ID: 29135769
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the role of Section 1115 waivers on Medicaid coverage and utilization of opioid agonist therapy among substance use treatment admissions.
Tormohlen KN; Krawczyk N; Feder KA; Riehm KE; Crum RM; Mojtabai R
Health Serv Res; 2020 Apr; 55(2):232-238. PubMed ID: 31884703
[TBL] [Abstract][Full Text] [Related]
5. Financial factors and the implementation of medications for treating opioid use disorders.
Knudsen HK; Roman PM
J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
[TBL] [Abstract][Full Text] [Related]
6. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
[TBL] [Abstract][Full Text] [Related]
7. The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder.
Mojtabai R; Mauro C; Wall MM; Barry CL; Olfson M
Psychiatr Serv; 2019 Jul; 70(7):617-620. PubMed ID: 31035894
[TBL] [Abstract][Full Text] [Related]
8. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
Yang JC; Roman-Urrestarazu A; Brayne C
PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
[TBL] [Abstract][Full Text] [Related]
9. Cost of provision of opioid substitution therapy provision in Tijuana, Mexico.
Burgos JL; Cepeda JA; Kahn JG; Mittal ML; Meza E; Lazos RRP; Vargas PC; Vickerman P; Strathdee SA; Martin NK
Harm Reduct J; 2018 May; 15(1):28. PubMed ID: 29792191
[TBL] [Abstract][Full Text] [Related]
10. Methadone maintenance and state Medicaid managed care programs.
McCarty D; Frank RG; Denmead GC
Milbank Q; 1999; 77(3):341-62, 274. PubMed ID: 10526548
[TBL] [Abstract][Full Text] [Related]
11. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
[TBL] [Abstract][Full Text] [Related]
12. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
[TBL] [Abstract][Full Text] [Related]
13. Medicaid coverage, methadone maintenance, and felony arrests: outcomes of opiate treatment in two states.
Deck D; Wiitala W; McFarland B; Campbell K; Mullooly J; Krupski A; McCarty D
J Addict Dis; 2009; 28(2):89-102. PubMed ID: 19340671
[TBL] [Abstract][Full Text] [Related]
14. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective.
Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM
J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980
[TBL] [Abstract][Full Text] [Related]
15. Opioid use disorder during pregnancy in Tennessee: expediency vs. science.
Martin PR; Finlayson AJ
Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388
[TBL] [Abstract][Full Text] [Related]
16. Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.
Askari MS; Martins SS; Mauro PM
J Subst Abuse Treat; 2020 Jul; 114():108028. PubMed ID: 32527510
[TBL] [Abstract][Full Text] [Related]
17. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine.
Clark RE; Samnaliev M; Baxter JD; Leung GY
Health Aff (Millwood); 2011 Aug; 30(8):1425-33. PubMed ID: 21821560
[TBL] [Abstract][Full Text] [Related]
18. A call for evidence-based medical treatment of opioid dependence in the United States and Canada.
Nosyk B; Anglin MD; Brissette S; Kerr T; Marsh DC; Schackman BR; Wood E; Montaner JS
Health Aff (Millwood); 2013 Aug; 32(8):1462-9. PubMed ID: 23918492
[TBL] [Abstract][Full Text] [Related]
19. Economic vulnerability of methadone maintenance patients: Implications for policies on co-payment services.
Tran BX; Phan HT; Nguyen LH; Nguyen CT; Nguyen AT; Le TN; Latkin CA
Int J Drug Policy; 2016 May; 31():131-7. PubMed ID: 26922633
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Medications for Opioid Use Disorder Among West Virginia Medicaid Enrollees Following Medicaid Coverage of Methadone.
Harris SJ; Landis RK; Li W; Stein BD; Saloner B
Subst Use Addctn J; 2024 Jan; 45(1):91-100. PubMed ID: 38258853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
